Table 5.

Association of genetic score and lifestyle factors with plasma adiponectin levels among women (Nurses’ Health Study) and men (Health Professionals Follow-up Study)^*

Variable	Women (n = 2,217)			Men (n = 619)
	R2 (%)†	Relative change (95% CI), %‡	P	R2 (%)†	Relative change (95% CI), %‡	P
Genetic score§	2.82	5.56 (4.21 to 6.93)	<0.001	0.94	20.9 (6.78 to 36.9)	0.003
Age, y	1.98	3.00 (1.12 to 4.90)	0.002	0.59	3.09 (−0.18 to 6.46)	0.06
Body mass index, kg/m2	10.2	−15.2 (−17.0 to −13.4)	<0.001	4.56	−21.3 (−27.8 to −14.2)	<0.001
Physical activity, MET-hours/wk	0.52	0.34 (−0.20 to 0.88)	0.21	0.29	0.34 (−0.62 to 1.31)	0.49
Pack-years of smoking	0.01	−0.22 (−0.80 to 0.36)	0.46	0.02	0.36 (−0.99 to 1.72)	0.61
Alcohol consumption, g/d	0.71	1.44 (0.35 to 2.53)	0.009	0.31	1.21 (−0.59 to 3.04)	0.19
Regular aspirin/NSAID use	0.01	1.15 (−2.90 to 5.37)	0.58	0.01	−0.56 (−10.8 to 10.8)	0.92
Postmenopausal hormone use	2.56			-
Never		12.4 (4.37 to 21.1)	0.002		-	-
Ever		14.7 (6.83 to 23.1)	<0.001		-	-

^*Abbreviations: CI = confidence interval; MET = metabolic equivalent = (caloric need per kilogram body weight per hour activity)/(caloric need per kilogram body weight per hour at rest); NSAID = non-steroidal anti-inflammatory drug.

^†Percent of variation of adiponectin concentrations explained by each variable in the univariate linear regression model.

^‡Percent of change in adiponectin levels per 1-point increment in genetic score and 5-unit increment for continuous covariates, estimated in linear regression model including all variables in the first column. For aspirin/NSAID use, percentage of change was calculated for regular users relative to non-users. For postmenopausal use, percentage of change was relative to adiponectin levels among premenopausal women.

^§In women, the genetic score = 1.78 * no. of A alleles of rs17300539 + 1.49 * no. of G alleles of rs17366568 + 0.70 * no. of A alleles of rs6773957 + 0.65* no. of T alleles of rs1063538. In men, the genetic score = no. of G alleles of rs17366568.